

## *Supporting information*

# **Novel Perfluorinated Triblock Amphiphilic Copolymers for Lipid-shelled Microbubble Stabilization**

Yohann Corvis\*,<sup>†</sup> Simona Manta,<sup>†</sup> Caroline Thebault,<sup>†</sup> Olivier Couture,<sup>‡</sup> H       Dhotel,<sup>†</sup>  
Jean-Philippe Michel,<sup> , </sup> Johanne Seguin,<sup>†</sup> Michel Bessodes,<sup>†</sup> Philippe Espeau,<sup>†</sup>  
Chantal Pichon,<sup>  </sup> Cyrille Richard,<sup>†</sup> Nathalie Mignet<sup>†</sup>

<sup>†</sup>Paris Descartes University, Sorbonne Paris Cit  , Team vectors for molecular imaging and targeted therapy,  
CNRS UMR8258, INSERM U1022, Chimie ParisTech, PSL Research University, 4 avenue de l'Observatoire,  
75 006 Paris, France.

<sup>‡</sup>CNRS, INSERM, ESPCI ParisTech, PSL Research University, Institut Langevin, 75 005 Paris, France.

<sup> </sup>Univ Paris Sud, Institut Galien Paris Sud, Universit   Paris-Saclay, 5 rue Jean-Baptiste Cl      , 92 296  
Ch      -Malabry cedex, France.

<sup> </sup>CNRS, UMR 8612, 92 296 Ch      -Malabry, France.

<sup>  </sup>Centre de Biophysique Mol  culaire, UPR 4301, 45 071 Orl      , France.

\*Corresponding author: Yohann Corvis, CNRS UMR8258, INSERM U1022, Faculty of Pharmacy, 4 avenue de  
l'Observatoire, 75 006 Paris; e-mail: [yohann.corvis@parisdescartes.fr](mailto:yohann.corvis@parisdescartes.fr)

### **Content:**

Supporting Data (12 pages from S1 to S12; 12 figures from Figure S1 to Figure S12)

- Atri synthesis
- <sup>1</sup>H, <sup>13</sup>C NMR and mass spectra for compounds **1**, **5**, **6**, and **7**

### *Atri synthesis*

**11-(tert-butoxycarbonylamino)undecanoic acid (1)** : 11-aminoundecanoic acid (2 g; 10 mmol) was dissolved in dry methanol (50 mL) then triethylamine (1.7 mL; 1.2 mol eq) and  $\text{Boc}_2\text{O}$  (2.18 g; 1 mol eq) were added. The mixture was heated at 55°C for 20 min. TLC control in  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  (9:1) ascertained the end of the reaction. The solution was evaporated, taken up in diethyl ether and washed three times with 10% citric acid solution. The organic phase was dried over magnesium sulfate, filtered and concentrated.  $^1\text{H}$  NMR of **1** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  4.53 (bs, 1H); 3.10 (m, 2H); 2.34 (t, 2H); 1.63 (m, 2H); 1.44 (m, 11H); 1.27 (m, 11H).  $^{13}\text{C}$  NMR of **1** (100 MHz,  $\text{CDCl}_3$ )  $\delta$  179.5; 156.3; 79.0; 40.6; 34.3; 30.2; 29.5; 28.3; 26.8; 24.6. MS of **1**  $m/z$  325  $[\text{M}+\text{Na}]^+$ .

**PEGylation of 1**: Compound **1** (0.15 mmol; 45.2 mg) was dissolved in dichloromethane (5 mL) and reacted with the three different amino-methoxy-polyethylene glycols (0.10 mmol; MW= 500, 1000, 2000  $\text{g mol}^{-1}$ ) in three different experiments. Triethylamine (0.5 mmol; 0.07 mL) and BOP (0.12 mmol; 53 mg) were added, and the mixture was stirred at room temperature for 2 h. It was then diluted with dichloromethane (10 mL), washed twice with saturated NaCl and dried over  $\text{Na}_2\text{SO}_4$ . Concentration followed by precipitation in diethyl ether gave respectively **2**, **3** and **4** after centrifugation and several washes with diethyl ether.  $^1\text{H}$  NMR for **2** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.25 (bs, 1H); 4.53 (bs, 1H); 3.80 (m, 2H); 3.63 (m, 40H); 3.53 (m, 4H); 3.43 (m, 2H); 3.36 (s, 3H); 3.08 (m, 2H), 2.15 (m, 2H); 1.59 (m, 2H); 1.42 (s, 11H); 1.25 (m, 12H).  $^{13}\text{C}$  NMR for **2** (100 MHz,  $\text{CDCl}_3$ )  $\delta$  173.2; 153.6; 78.9; 71.8; 70.6; 69.9; 59.2; 40.7; 39.0; 36.0; 30.0; 29.1; 28.3; 26.7; 25.9. MS for **2**  $m/z$  881  $[\text{M}+\text{K}]^+$ .  $^1\text{H}$  NMR for **3** (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.25 (bs, 1H); 4.53 (bs, 1H); 3.80 (m, 2H); 3.63 (m, 92H); 3.53 (m, 4H); 3.43 (m, 2H); 3.36 (s, 3H); 3.08 (m, 2H), 2.15 (m, 2H); 1.59 (m, 2H); 1.42 (s, 11H); 1.25 (m, 12H).  $^{13}\text{C}$  NMR for **3** (100 MHz,  $\text{CDCl}_3$ )  $\delta$  173.3; 156.0; 78.9; 71.9; 70.5;

59.1; 46.1; 40.5; 39.0; 36.5; 29.9; 29.3; 28.5; 26.8; 25.8. MS for **3** m/z 1393.7 [M+K]<sup>+</sup>. <sup>1</sup>H NMR for **4** (400 MHz, CDCl<sub>3</sub>) δ 6.20 (bs, 1H); 4.53 (bs, 1H); 3.80 (m, 2H); 3.63 (m, 174H); 3.53 (m, 6H); 3.43 (m, 4H); 3.36 (s, 3H); 3.08 (m, 2H), 2.15 (m, 2H); 1.59 (m, 2H); 1.49 (m, 2H); 1.42 (s, 9H); 1.25 (m, 12H). <sup>13</sup>C NMR for **4** (100 MHz, CDCl<sub>3</sub>) δ 173.5; 161.6; 155.8; 91.9; 80.7; 78.7; 71.9; 70.5; 68.8; 65.9; 58.9; 49.8; 45.8; 40.4; 39.0; 37.7; 36.7; 30.2; 29.2; 28.3; 26.6; 25.6; 15.4. MS for **4** m/z 2321 [M+Na]<sup>+</sup>, 2337 [M+K]<sup>+</sup>.

**Boc deprotection:** Compounds **2**, **3** and **4** (1.5 mmol) were treated with trifluoroacetic acid (1.5 mL) in CH<sub>2</sub>Cl<sub>2</sub> (9 mL) (three separate reactions) under stirring at ambient temperature for 2 h. The reaction media were evaporated and traces of TFA removed by coevaporation with chloroform. The residues were washed with diethyl ether (caution: in the case of the 500 g.mol<sup>-1</sup> PEG, the product **5** is quite soluble in ether, it should then be washed at 0°C). Products **5**, **6** and **7** were obtained as white powders. <sup>1</sup>H NMR for **5** (400 MHz) CDCl<sub>3</sub> δ 7.34 (bs, 1H); 6.79 (bs, 3H); 3.64 (m, 44H); 3.44 (m, 2H); 3.38 (s, 3H); 2.90 (m, 2H); 2.20 (m, 2H); 1.63 (m, 4H); 1.29 (m, 12H). <sup>13</sup>C NMR for **5** (100 MHz, CDCl<sub>3</sub>) δ 176.4; 159; 115; 71.5; 70.2; 69.1; 58.8; 40.4; 36.4; 39.5; 35.6; 29.8; 28.6; 27.4; 26.1; 25.4. MS for **5** m/z 743 [M+H]<sup>+</sup>, 765 [M+Na]<sup>+</sup>, 781 [M+K]<sup>+</sup>. <sup>1</sup>H NMR for **6** (400 MHz) CDCl<sub>3</sub> δ 7.34 (bs, 1H); 6.90 (bs, 2H); 3.64 (m, 90H); 3.44 (m, 2H); 3.38 (s, 3H); 3.20 (m, 2H); 2.90 (m, 2H); 2.20 (m, 2H); 1.63 (m, 9H); 1.29 (m, 12H). MS for **6** m/z 1271 [M+H]<sup>+</sup>, 1293 [M+K]<sup>+</sup>. <sup>1</sup>H NMR for **7** (400 MHz) CDCl<sub>3</sub> δ 7.34 (bs, 1H); 6.79 (bs, 2H); 3.80 (m, 2H); 3.64 (m, 178H); 3.44 (m, 2H); 3.38 (s, 3H); 3.26 (m, 2H); 2.90 (m, 2H); 2.20 (m, 2H); 1.63 (m, 2H); 1.29 (m, 12H). <sup>13</sup>C NMR for **7** (100 MHz, CDCl<sub>3</sub>) δ 176.5; 158.5; 115; 71.7; 70.1; 68.8; 58.5; 46.3; 40.4; 39.7; 38.8; 35.7; 28.8; 27.4; 26.3; 25.7. MS for **7** m/z 2221 [M+H]<sup>+</sup>.

**Atri500, 1000 and 2000:** The above compounds **5**, **6** and **7** (1.5 mmol) were independently reacted with heptadecafluorodecyl isocyanate (0.88 g; 1.8 mmol) and triethylamine (4.5


mmol; 0.63 mL) in THF (10 mL). Completion of the reaction was determined by TLC using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (8:2) as eluting solvent. The solution was evaporated, the residue was dissolved in a minimum amount of methanol. Purification was obtained using a short column loaded with ion exchange resin (Waters Rxn Cx sulfonate) eluted with methanol. The eluate was evaporated and the residue lyophilized in water to give respectively products **8**, **9** and **10**.

<sup>1</sup>H NMR for **8** (400 MHz) CDCl<sub>3</sub> δ 6.48 (bs, 1H); 3.65 (m, 44H), 3.58 (m, 4H); 3.45 (m, 2H); 3.40 (m, 2H); 3.35 (s, 3H); 3.18 (m, 2H); 2.38 (m, 2H); 2.30 (m, 2H), 1.62 (m, 2H); 1.45 (m, 2H); 1.25 (m, 12H). <sup>13</sup>C NMR for **8** (100 MHz) CDCl<sub>3</sub> δ 173.7; 158.5; 71.9; 70.6; 70.2; 69.9; 59.0; 40.2; 39.1; 36.5; 32.5; 31.7; 30.1; 28.6; 26.7; 25.6. <sup>19</sup>F NMR for **8** (377 MHz) δ -81.7; -114.8; -122.7; -123.5; -124.4; -126.9. MS for **8** m/z = 1298.60 (M+Na).


<sup>1</sup>H NMR for **9** (400 MHz) CDCl<sub>3</sub> δ 6.38 (m, 1H); 5.25 (m, 1H); 5.02 (m, 1H); 3.65 (m, 90H); 3.55 (m, 4H); 3.50 (m, 2H); 3.45 (m, 2H); 3.25 (s, 3H); 3.18 (m, 2H); 1.62 (m, 2H); 1.45 (m, 2H); 1.22 (m, 14H). <sup>13</sup>C NMR for **9** (100 MHz) CDCl<sub>3</sub> δ 173.4; 158.2; 71.9; 70.4; 70.1; 69.9; 59.0; 40.2; 39.0; 36.5; 36.0; 32.5; 30.1; 29.0; 26.6; 25.5. <sup>19</sup>F NMR for **9** (377 MHz) δ -81.5; -114.6; -115.2; -122.5; -123.3; -124.2; -126.8; -127.0. MS for **9** m/z = 1712.26 (M+Na).

<sup>1</sup>H NMR for **10** (400 MHz) CDCl<sub>3</sub> δ 6.50 (bs, 1H); 5.20 (bs, 1H); 4.95 (bs, 1H); 3.81 (m, 2H); 3.64 (m, 204H); 3.55 (m, 6H); 3.44 (m, 4H); 3.37 (s, 3H); 3.13 (m, 2H); 2.35 (m, 2H); 2.17 (m, 2H); 1.61 (m, 2H); 1.46 (m, 2H); 1.27 (m, 12H). <sup>13</sup>C NMR for **10** (100 MHz) CDCl<sub>3</sub> δ 173.5; 158.4; 71.8; 70.3; 70.0; 69.0; 59.1; 40.1; 39.1; 36.6; 28.9; 26.8; 25.5. <sup>19</sup>F NMR for **10** (377 MHz) δ (from TFA) = -81.72; -114.94; -122.67; -123.71; -124.63; -127.12; -127.78. MS for **10** m/z = 2684.39; 2707.39 (M+Na); 2723.38 (M+K).

*<sup>1</sup>H, <sup>13</sup>C NMR and mass spectra for compounds 1, 5, 6, and 7.*



**Figure S1.** <sup>1</sup>H NMR spectrum for compound 1.



**Figure S2.** <sup>13</sup>C NMR spectrum for compound 1.








Figure S3. Mass spectrum for compound 1.



**Figure S4.**  $^1\text{H}$  NMR spectrum for compound **5**.




**Figure S5.**  $^{13}\text{C}$  NMR spectrum for compound **5**.




\\...at 500.T2D  
Acquired:

Figure S6. Mass spectrum for compound 5.







**Figure S7.**  $^1\text{H}$  NMR spectrum for compound **6**.




**Figure S8.**  $^{13}\text{C}$  NMR spectrum for compound **6**.




\\...lat 1000.T2D  
Acquired:

Figure S9. Mass spectrum for compound 6.




**Figure S10.**  $^1\text{H}$  NMR spectrum for compound 7.




**Figure S11.**  $^{13}\text{C}$  NMR spectrum for compound 7.

4700 Reflector Spec #1[BP = 2175.1, 2112]



<<at 2000>> 4700 Reflector Spec #1[BP = 2175.1, 2112]



\\...at 2000.T2D  
Acquired:

Figure S12. Mass spectrum for compound 7.